Geode Capital Management LLC Has $8.43 Million Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Geode Capital Management LLC cut its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 2.3% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 56,448 shares of the biotechnology company’s stock after selling 1,338 shares during the period. Geode Capital Management LLC owned about 0.09% of Ascendis Pharma A/S worth $8,428,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $60,000. Janus Henderson Group PLC lifted its holdings in shares of Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock worth $625,075,000 after purchasing an additional 267,881 shares during the period. Avoro Capital Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock worth $572,341,000 after purchasing an additional 229,995 shares during the period. Westfield Capital Management Co. LP grew its stake in shares of Ascendis Pharma A/S by 3.4% in the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock worth $766,523,000 after purchasing an additional 170,942 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after purchasing an additional 155,971 shares during the period.

Ascendis Pharma A/S Trading Up 0.2 %

Shares of NASDAQ ASND opened at $138.00 on Friday. The firm has a market capitalization of $8.37 billion, a P/E ratio of -17.08 and a beta of 0.67. The firm’s 50-day moving average price is $131.43 and its 200-day moving average price is $133.13. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $161.00.

Analyst Upgrades and Downgrades

ASND has been the topic of several recent research reports. Wells Fargo & Company lifted their target price on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. JPMorgan Chase & Co. dropped their price target on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 23rd. Finally, TD Cowen decreased their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.